Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

British Journal of Cancer

Volumn 100, Issue 6, 2009, Pages 881-887

  Catalano, V ^a   Loupakis, F ^b   Graziano, F ^a   Torresi, U ^c   Bisonni, R ^d   Mari, D ^e   Fornaro, L ^b   Baldelli, A M ^a   Giordani, P ^a   Rossi, D ^a   Alessandroni, P ^a   Giustini, L ^d   Silva, R R ^e   Falcone, A ^b   D'Emidio, S ^a   Fedeli, S L ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c Ospedale Generale Provinciale di Macerata   (Italy)

^d Ospedale 'A Murri'   (Italy)

^e Medical Oncology   (Italy)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Mucinous; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; EASTERN COOPERATIVE ONCOLOGY GROUP; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; OVERALL SURVIVAL; PERFORMANCE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 62549089251     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604955     Document Type: Article

References (36)

1. Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66-73
2. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446
3. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MKB, Seymour MT (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26: 2690-2698
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000a) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88: 1739-1757
5. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000b) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994
6. Connelly JH, Robey-Cafferty SS, Cleary KR (1991) Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. Arch Pathol Lab Med 115: 1022-1025
7. Consorti F, Lorenzotti A, Midiri G, Di Paola M (2000) Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 73: 70-74
8. Enriquez JM, Diez M, Tobaruela E, Lozano O, Domínguez P, González A, Mugüerza JM, Ratia T (1998) Clinical, histopathological, cytogenetic and prognostic differences between mucinous and nonmucinous colorectal adenocarcinomas. Rev Esp Enferm Dig 90: 563-572
9. Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL (2005) Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 92: 259-264
10. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson III AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12: 38-50
11. Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright Jr JB, Ray JE (1993) Mucinous carcinoma - just another colon cancer? Dis Colon Rectum 36: 49-54
12. Grothey A, Marshall JL (2007) Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology 21: 553-564
13. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214
14. Hamilton SR, Aaltonen LA (2000) Pathology and Genetics, Tumours of the Digestive System. World Health Organization Classification of Tumours, 3rd edn. IARC: Lyon
15. Hanski C (1995) Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer 72: 1350-1356
16. Kakar S, Aksoy S, Burgart L, Smyrk T (2004) Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 17: 696-700
17. Kanemitsu Y, Kato T, Hirai T, Yasui K, Morimoto T, Shimizu Y, Kodera Y, Yamamura Y (2003) Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 46: 160-167
18. Kim DH, Kim JW, Cho JH, Baek SH, Kakar S, Kim GE, Sleisenger MH, Kim YS (2005) Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol 27: 957-964
19. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5: 2
20. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherübl H, Boland CR, Zeitz M, Hanski C (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101: 23-31
21. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT (1987) Colloid carcinoma of the colon and rectum. Cancer 60: 3103-3112
22. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll SH, Porschen R, Schmiegel W, Graeven U (2008) Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 23: 1033-1039
23. Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ (2005) Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16: 1305-1310
24. Ogino S, Brahmandam M, Cantor M, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS (2006) Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19: 59-68
25. Parham D (1923) Colloid carcinoma. Ann Surg 77: 90-105
26. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618
27. Sarli L, Bottarelli L, Azzoni C, Di Cola G, Barilli AL, Costi R, Mazzeo A, Salvemini C, Porrini C, Cecchini S, Taglia M, Roncoroni L, Bordi C (2008) Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 15: 1429-1439
28. Secco GB, Fardelli R, Campora E, Lapertosa G, Gentile R, Zoli S, Prior C (1994) Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. Oncology 51: 30-34
29. Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS (2005) Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol 26: 745-750
30. Symonds DA, Vickery AL (1976) Mucinous carcinoma of the colon and rectum. Cancer 37: 1891-1900
31. Tanaka H, Deng G, Matsuzaki K, Kakar S, Kim GE, Miura S, Sleisenger MH, Kim YS (2006) BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 118: 2765-2771
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
33. Umpleby HC, Ranson DL, Williamson RC (1985) Peculiarities of mucinous colorectal carcinoma. Br J Surg 72: 715-718
34. Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22: 739-748
35. Younes M, Katikaneni PR, Lechago J (1993) The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer 72: 3588-3592
36. Zhang H, Evertsson S, Sun X (1999) Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol 14: 1057-1061